Clinical Trials Related to Pembrolizumab

Related studies linked through entity extraction aliases.

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Status: TERMINATED
Phase: PHASE3

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

Status: COMPLETED
Phase: PHASE3

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Status: COMPLETED
Phase: PHASE1/PHASE2

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

Status: COMPLETED
Phase: PHASE1

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Status: WITHDRAWN
Phase: PHASE2

Pembrolizumab for Newly Diagnosed Glioblastoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Status: COMPLETED
Phase: PHASE2

Pan Tumor Rollover Study

Status: RECRUITING
Phase: PHASE2

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Status: COMPLETED
Phase: PHASE3

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

Status: TERMINATED
Phase: PHASE1

Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

Status: WITHDRAWN
Phase: PHASE4

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Status: COMPLETED
Phase: PHASE1

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

Status: COMPLETED
Phase: PHASE3

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

Status: WITHDRAWN
Phase: PHASE3

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Status: TERMINATED
Phase: PHASE1

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

Status: COMPLETED
Phase: PHASE3

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

Status: COMPLETED
Phase: PHASE1